Chronic myelogenous leukaemia (CML) is a type of myeloproliferative disease characterized by the specific chromosomal translocation (so called Philadelphia chromosome), resulting in the fusion between the Abelson (Abl) tyrosine kinase gene on chromosome 9 and the break point cluster (Bcr) gene on chromosome 22. This fusion produces the BCR-ABL1 oncogene expressing constitutively active tyrosine kinase. CMLs are usually sensitive to treatment with tyrosine kinase inhibitors but in the course of treatment may develop resistance due to the secondary T315I point mutation in Abl kinase domain. Detection of T315I mutation can help in managing those patients who are not responding to current front-line CML therapies.
ABL-MMD-PCR Mutation Test Kit enables detection of T315I mutation in ABL gene against a background of wild-type genomic DNA.
The GeneFirst OncoPlex® ABL Mutation Test Kit (RUO) is a real-time PCR-based test that detectsT315I activating mutation in the human BCR-ABL1 gene with high sensitivity. This test is based on the GeneFirst proprietary technology, MMD, which is a combination of specially designedmutation-specific primers, blocker-probe and unique cycling conditions that facilitate selective amplification of multiple mutant alleles – at the same time, blocking amplification from wild type (normal) allele. This allows for the detection of rare mutations against a high background of normal, non-mutated genomic DNA.
